Åsa Rembratt

609 total citations
14 papers, 482 citations indexed

About

Åsa Rembratt is a scholar working on Cellular and Molecular Neuroscience, Urology and Neurology. According to data from OpenAlex, Åsa Rembratt has authored 14 papers receiving a total of 482 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Cellular and Molecular Neuroscience, 5 papers in Urology and 4 papers in Neurology. Recurrent topics in Åsa Rembratt's work include Urinary Bladder and Prostate Research (5 papers), Genetic Neurodegenerative Diseases (5 papers) and Neurological disorders and treatments (4 papers). Åsa Rembratt is often cited by papers focused on Urinary Bladder and Prostate Research (5 papers), Genetic Neurodegenerative Diseases (5 papers) and Neurological disorders and treatments (4 papers). Åsa Rembratt collaborates with scholars based in Denmark, Sweden and Germany. Åsa Rembratt's co-authors include Jens Peter Nørgaard, A. Riis, K‐E. Andersson, Karin Andersson, Karl‐Erik Andersson, Anne Rosser, Ralf Reilmann, G. Bernhard Landwehrmeyer, Ferdinando Squitieri and Roger A. Barker and has published in prestigious journals such as Neurology, The Lancet Neurology and British Journal of Clinical Pharmacology.

In The Last Decade

Åsa Rembratt

14 papers receiving 466 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Åsa Rembratt Denmark	8	229	133	132	103	101	14	482
Takakazu Yunoki Japan	13	272 1.2×	53 0.4×	148 1.1×	108 1.0×	12 0.1×	31	469
Sebastian Schneider Germany	13	90 0.4×	40 0.3×	82 0.6×	59 0.6×	12 0.1×	31	418
Tatsuya Miyamoto Japan	10	123 0.5×	16 0.1×	190 1.4×	32 0.3×	15 0.1×	46	583
Louise Johnston United Kingdom	12	231 1.0×	54 0.4×	218 1.7×	85 0.8×	3 0.0×	15	509
W Isler Switzerland	12	16 0.1×	72 0.5×	156 1.2×	73 0.7×	104 1.0×	34	511
Richard Flint New Zealand	12	21 0.1×	98 0.7×	57 0.4×	30 0.3×	11 0.1×	33	352
Peter Hunter United Kingdom	9	38 0.2×	41 0.3×	52 0.4×	90 0.9×	10 0.1×	20	467
David H. Lau United Kingdom	13	44 0.2×	127 1.0×	185 1.4×	10 0.1×	13 0.1×	26	579
Yuehong Tong United States	12	49 0.2×	41 0.3×	76 0.6×	19 0.2×	9 0.1×	25	412

Countries citing papers authored by Åsa Rembratt

Since Specialization

Citations

This map shows the geographic impact of Åsa Rembratt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Åsa Rembratt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Åsa Rembratt more than expected).

Fields of papers citing papers by Åsa Rembratt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Åsa Rembratt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Åsa Rembratt. The network helps show where Åsa Rembratt may publish in the future.

Co-authorship network of co-authors of Åsa Rembratt

This figure shows the co-authorship network connecting the top 25 collaborators of Åsa Rembratt. A scholar is included among the top collaborators of Åsa Rembratt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Åsa Rembratt. Åsa Rembratt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Rabinovich‐Guilatt, Laura, et al.. (2015). The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease. British Journal of Clinical Pharmacology. 81(2). 246–255. 4 indexed citations

Acha, Virginia, et al.. (2014). Tell me the whole story: the role of product labelling in building user confidence in biosimilars in Europe. Generics and Biosimilars Initiative Journal. 3(4). 188–192. 7 indexed citations

Squitieri, Ferdinando, G. Bernhard Landwehrmeyer, Ralf Reilmann, et al.. (2013). One-year safety and tolerability profile of pridopidine in patients with Huntington disease. Neurology. 80(12). 1086–1094. 16 indexed citations

Rembratt, Åsa, et al.. (2012). Pharmacokinetic and tolerability profile of pridopidine in healthy-volunteer poor and extensive CYP2D6 metabolizers, following single and multiple dosing. European Journal of Drug Metabolism and Pharmacokinetics. 38(1). 43–51. 4 indexed citations

Yébenes, Justo García de, G. Bernhard Landwehrmeyer, Ferdinando Squitieri, et al.. (2011). Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet Neurology. 10(12). 1049–1057. 131 indexed citations

Tedroff, Joakim, et al.. (2010). Poster 20: Pridopidine (ACR16) in Huntington's Disease: An Update on the MermaiHD and HART Studies. Neurotherapeutics. 7(1). 144–145. 1 indexed citations

Rembratt, Åsa, et al.. (2008). Overnight testing of renal concentrating capacity in children using desmopressin tablets: Sensitivity, repeatability and non-inferiority versus intranasal spray. Scandinavian Journal of Urology and Nephrology. 42(3). 274–277. 1 indexed citations

Rembratt, Åsa, A. Riis, & Jens Peter Nørgaard. (2005). Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia. Neurourology and Urodynamics. 25(2). 105–109. 91 indexed citations

Rembratt, Åsa, et al.. (2004). Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55?70�years. European Journal of Clinical Pharmacology. 60(6). 397–402. 54 indexed citations

10.

Rembratt, Åsa, Jens Peter Nørgaard, & Karin Andersson. (2003). Nocturia and associated morbidity in a community‐dwelling elderly population. British Journal of Urology. 92(7). 726–730. 59 indexed citations

11.

Rembratt, Åsa, Jens Peter Nørgaard, & K‐E. Andersson. (2003). Desmopressin in elderly patients with nocturia: short‐term safety and effects on urine output, sleep and voiding patterns. British Journal of Urology. 91(7). 642–646. 43 indexed citations

12.

Rembratt, Åsa, Jens Peter Nørgaard, & Karl‐Erik Andersson. (2003). Differences between nocturics and non‐nocturics in voiding patterns: an analysis of frequency‐volume charts from community‐dwelling elderly. British Journal of Urology. 91(1). 45–50. 41 indexed citations

13.

Rembratt, Åsa, et al.. (2002). What is nocturnal polyuria?. British Journal of Urology. 90(s3). 18–20. 26 indexed citations

14.

Mårild, Staffan, Åsa Rembratt, Ulf Jodal, & Jens Peter Nørgaard. (2001). Renal concentrating capacity test using desmopressin at bedtime. Pediatric Nephrology. 16(5). 439–442. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact